A novel rapamycin analog is highly selective for mTORC1 in vivo

Rapamycin extends lifespan in model organisms by targeting mTORC1, but exerts off-target side effects via inhibition of mTORC2. Here, the authors report the identification of a selective mTORC1 inhibitor, and show that it inhibits mTORC1 activity both in vitro and in vivo, with reduced side effects...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Katherine H. Schreiber, Sebastian I. Arriola Apelo, Deyang Yu, Jacqueline A. Brinkman, Michael C. Velarde, Faizan A. Syed, Chen-Yu Liao, Emma L. Baar, Kathryn A. Carbajal, Dawn S. Sherman, Denise Ortiz, Regina Brunauer, Shany E. Yang, Stelios T. Tzannis, Brian K. Kennedy, Dudley W. Lamming
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2019
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/62fe1b728b0148059e306c8857df6c69
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:62fe1b728b0148059e306c8857df6c69
record_format	dspace
spelling	oai:doaj.org-article:62fe1b728b0148059e306c8857df6c692021-12-02T16:51:00ZA novel rapamycin analog is highly selective for mTORC1 in vivo10.1038/s41467-019-11174-02041-1723https://doaj.org/article/62fe1b728b0148059e306c8857df6c692019-07-01T00:00:00Zhttps://doi.org/10.1038/s41467-019-11174-0https://doaj.org/toc/2041-1723Rapamycin extends lifespan in model organisms by targeting mTORC1, but exerts off-target side effects via inhibition of mTORC2. Here, the authors report the identification of a selective mTORC1 inhibitor, and show that it inhibits mTORC1 activity both in vitro and in vivo, with reduced side effects on glucose homeostasis, lipid metabolism, and the immune system.Katherine H. SchreiberSebastian I. Arriola ApeloDeyang YuJacqueline A. BrinkmanMichael C. VelardeFaizan A. SyedChen-Yu LiaoEmma L. BaarKathryn A. CarbajalDawn S. ShermanDenise OrtizRegina BrunauerShany E. YangStelios T. TzannisBrian K. KennedyDudley W. LammingNature PortfolioarticleScienceQENNature Communications, Vol 10, Iss 1, Pp 1-12 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Katherine H. Schreiber Sebastian I. Arriola Apelo Deyang Yu Jacqueline A. Brinkman Michael C. Velarde Faizan A. Syed Chen-Yu Liao Emma L. Baar Kathryn A. Carbajal Dawn S. Sherman Denise Ortiz Regina Brunauer Shany E. Yang Stelios T. Tzannis Brian K. Kennedy Dudley W. Lamming A novel rapamycin analog is highly selective for mTORC1 in vivo
description	Rapamycin extends lifespan in model organisms by targeting mTORC1, but exerts off-target side effects via inhibition of mTORC2. Here, the authors report the identification of a selective mTORC1 inhibitor, and show that it inhibits mTORC1 activity both in vitro and in vivo, with reduced side effects on glucose homeostasis, lipid metabolism, and the immune system.
format	article
author	Katherine H. Schreiber Sebastian I. Arriola Apelo Deyang Yu Jacqueline A. Brinkman Michael C. Velarde Faizan A. Syed Chen-Yu Liao Emma L. Baar Kathryn A. Carbajal Dawn S. Sherman Denise Ortiz Regina Brunauer Shany E. Yang Stelios T. Tzannis Brian K. Kennedy Dudley W. Lamming
author_facet	Katherine H. Schreiber Sebastian I. Arriola Apelo Deyang Yu Jacqueline A. Brinkman Michael C. Velarde Faizan A. Syed Chen-Yu Liao Emma L. Baar Kathryn A. Carbajal Dawn S. Sherman Denise Ortiz Regina Brunauer Shany E. Yang Stelios T. Tzannis Brian K. Kennedy Dudley W. Lamming
author_sort	Katherine H. Schreiber
title	A novel rapamycin analog is highly selective for mTORC1 in vivo
title_short	A novel rapamycin analog is highly selective for mTORC1 in vivo
title_full	A novel rapamycin analog is highly selective for mTORC1 in vivo
title_fullStr	A novel rapamycin analog is highly selective for mTORC1 in vivo
title_full_unstemmed	A novel rapamycin analog is highly selective for mTORC1 in vivo
title_sort	novel rapamycin analog is highly selective for mtorc1 in vivo
publisher	Nature Portfolio
publishDate	2019
url	https://doaj.org/article/62fe1b728b0148059e306c8857df6c69
work_keys_str_mv	AT katherinehschreiber anovelrapamycinanalogishighlyselectiveformtorc1invivo AT sebastianiarriolaapelo anovelrapamycinanalogishighlyselectiveformtorc1invivo AT deyangyu anovelrapamycinanalogishighlyselectiveformtorc1invivo AT jacquelineabrinkman anovelrapamycinanalogishighlyselectiveformtorc1invivo AT michaelcvelarde anovelrapamycinanalogishighlyselectiveformtorc1invivo AT faizanasyed anovelrapamycinanalogishighlyselectiveformtorc1invivo AT chenyuliao anovelrapamycinanalogishighlyselectiveformtorc1invivo AT emmalbaar anovelrapamycinanalogishighlyselectiveformtorc1invivo AT kathrynacarbajal anovelrapamycinanalogishighlyselectiveformtorc1invivo AT dawnssherman anovelrapamycinanalogishighlyselectiveformtorc1invivo AT deniseortiz anovelrapamycinanalogishighlyselectiveformtorc1invivo AT reginabrunauer anovelrapamycinanalogishighlyselectiveformtorc1invivo AT shanyeyang anovelrapamycinanalogishighlyselectiveformtorc1invivo AT steliosttzannis anovelrapamycinanalogishighlyselectiveformtorc1invivo AT briankkennedy anovelrapamycinanalogishighlyselectiveformtorc1invivo AT dudleywlamming anovelrapamycinanalogishighlyselectiveformtorc1invivo AT katherinehschreiber novelrapamycinanalogishighlyselectiveformtorc1invivo AT sebastianiarriolaapelo novelrapamycinanalogishighlyselectiveformtorc1invivo AT deyangyu novelrapamycinanalogishighlyselectiveformtorc1invivo AT jacquelineabrinkman novelrapamycinanalogishighlyselectiveformtorc1invivo AT michaelcvelarde novelrapamycinanalogishighlyselectiveformtorc1invivo AT faizanasyed novelrapamycinanalogishighlyselectiveformtorc1invivo AT chenyuliao novelrapamycinanalogishighlyselectiveformtorc1invivo AT emmalbaar novelrapamycinanalogishighlyselectiveformtorc1invivo AT kathrynacarbajal novelrapamycinanalogishighlyselectiveformtorc1invivo AT dawnssherman novelrapamycinanalogishighlyselectiveformtorc1invivo AT deniseortiz novelrapamycinanalogishighlyselectiveformtorc1invivo AT reginabrunauer novelrapamycinanalogishighlyselectiveformtorc1invivo AT shanyeyang novelrapamycinanalogishighlyselectiveformtorc1invivo AT steliosttzannis novelrapamycinanalogishighlyselectiveformtorc1invivo AT briankkennedy novelrapamycinanalogishighlyselectiveformtorc1invivo AT dudleywlamming novelrapamycinanalogishighlyselectiveformtorc1invivo
_version_	1718382981213585408

A novel rapamycin analog is highly selective for mTORC1 in vivo

Ejemplares similares